Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy

Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy

Humoral vaccine responses are known to be suboptimal in patients receiving B-cell targeted therapy, and little is known about vaccine induced T-cell immunity in these patients. In this study, we characterized humoral and cellular antigen-specific anti-SARS-CoV2 responses following COVID-19 vaccinati...

Full description

Bibliographic Details
Main Authors: Paige K. Marty, Virginia P. Van Keulen, Courtney L. Erskine, Maleeha Shah, Amber Hummel, Michael Stachowitz, Samantha Fatis, Dane Granger, Matthew S. Block, Alí Duarte-García, Kenneth J. Warrington, Elitza S. Theel, Xian Zhou, Hu Zeng, Ulrich Specks, Patricio Escalante, Tobias Peikert
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-01-01
Series:Frontiers in Immunology
Subjects:
COVID-19 vaccination
rituximab
ANCA-associated vasculitis
cellular immune response
humoral immune response
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.834981/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.834981/full

Similar Items